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LETTER
Response to ‘Serum level of adiponectin is a
surrogate independent biomarker of radiographic
disease progression in early rheumatoid arthritis:
results from the ESPOIR cohort’– authors’ reply
Eric Toussirot1* and Gilles Dumoulin2,3
See related research by Meyer et al., http://arthritis-research.com/content/15/6/R210 and related letter by Sellam et al., http://arthritis-research.com/content/16/
2/408
We read with great interest the recent article in Arthritis
Research & Therapy in which Meyer and colleagues eval-
uated different circulating adipokines in patients with
recent-onset rheumatoid arthritis (RA) [1]. The authors
found that total adiponectin was independently associ-
ated with baseline radiographic score and with a change
in this score over time. The authors concluded that total
adiponectin at the time of diagnosis is a surrogate
marker for radiographic progression in early RA.
However, there are some compelling reasons why the
role of adiponectin in RA requires further elucidation.
The conclusion by Meyer and colleagues should thus be
tempered.
First, several studies have investigated circulating con-
centrations of leptin, adiponectin, visfatin and resistin in
RA, showing, in general, elevated levels. However, the
link between these adipose products and disease activity
remains controversial.
Second, both proinflammatory and anti-inflammatory
effects of adiponectin have been reported.
Third, adiponectin exists in various isoforms, mono-
mers and multimers. These different isoforms perform
distinct and sometimes counteracting biological func-
tions: low molecular weight adiponectin has been shown
to inhibit lipopolysaccharide-mediated IL-6 release and
to stimulate IL-10 secretion [2]. Conversely, high mo-
lecular weight (HMW) adiponectin induces secretion of
IL-6 by monocytes, and increases production of mono-
cyte chemoattractant protein-1 and IL-8 by peripheral
blood mononuclear cells and microvascular endothelial
cells [3].
Fourth, in a cross-sectional study, we evaluated total
adiponectin and HMW adiponectin in patients with
established RA and in healthy controls. We found that
circulating HMW adiponectin did not differ between pa-
tients and controls, whereas total adiponectin was ele-
vated in the RA group. In addition, total adiponectin
and HMW adiponectin did not correlate in this series
[4].
Fifth, adiponectin has been shown to be associated
with disease severity or joint destruction in both cross-
sectional and longitudinal studies with conflicting results
[1]. Moreover, in a murine collagen-induced arthritis
model of RA, total adiponectin was shown to attenuate
the severity of arthritis [5].
Finally, studies conducted to date in RA measured ex-
clusively total adiponectin and not its isoforms, and the
discrepancies between the findings of these studies may
be explained by the distinct biological properties of the
different adiponectin isoforms. In this context, no formal
conclusion may be drawn about the role of adiponectin
in disease activity and severity in RA. Future studies
evaluating adiponectin in RA and its relationships with
radiographic progression should include assessment of
the different adiponectin isoforms.
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